Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial
Top Cited Papers
- 1 October 2007
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 370 (9594), 1209-1218
- https://doi.org/10.1016/s0140-6736(07)61537-2
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMA—Italian Multiple Myeloma NetworkJournal of Clinical Oncology, 2007
- Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 studyBlood, 2006
- Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trialThe Lancet, 2006
- Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapyBlood, 2006
- Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 2006
- International Staging System for Multiple MyelomaJournal of Clinical Oncology, 2005
- Single versus Double Autologous Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2003
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- Multiple MyelomaNew England Journal of Medicine, 1997
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958